Hedin et al21 found that in 18 patients with PSC-IBD with cirrhosis, treated with anti-TNF alpha inhibitors, the median baseline ALP and total bilirubin levels did not change significantly over 6- or 12- month follow-up period. Here, TNF is linked to inflammatory bowel disease.